Compare STGW & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STGW | ARDX |
|---|---|---|
| Founded | 1980 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 2006 | 2014 |
| Metric | STGW | ARDX |
|---|---|---|
| Price | $6.07 | $6.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | $8.39 | ★ $15.14 |
| AVG Volume (30 Days) | 1.3M | ★ 4.1M |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,909,000,000.00 | $2,607,000.00 |
| Revenue This Year | $13.27 | $37.75 |
| Revenue Next Year | $4.07 | $34.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 2.39 | N/A |
| 52 Week Low | $4.03 | $3.54 |
| 52 Week High | $7.52 | $8.40 |
| Indicator | STGW | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 41.63 | 45.83 |
| Support Level | $5.86 | $5.54 |
| Resistance Level | $6.50 | $6.44 |
| Average True Range (ATR) | 0.27 | 0.36 |
| MACD | -0.08 | -0.05 |
| Stochastic Oscillator | 25.17 | 27.02 |
Stagwell Inc is a challenger network using AI to deliver marketing and advertising solutions to its clients. It operates in five reportable segments: Marketing Services, Digital Transformation, Media and Commerce, Communications, and The Marketing Cloud. Maximum revenue is generated from the Marketing Services segment, which offers social media solutions, designs breakthrough brand campaigns, and creates immersive experiential marketing programs and social engagement strategies, helping clients connect with audiences across digital platforms. The various brands operating under this segment include 72 and Sunny, Anomaly, NRG, Harris Insights, TEAM, and Movers & Shaker. Geographically, the company generates maximum revenue from the United States, followed by the UK and other countries.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.